Lobbying registration dated 2026-03-30
Registrant: Gaby Bourbara
Client: AstraZeneca Canada Inc.
Targeted institutions:
Atlantic Canada Opportunities Agency (ACOA)
Canadian Institutes of Health Research (CIHR)
Royal Canadian Mounted Police (RCMP)
Treasury Board Of Canada Secretariat (TBS)
Public Services and Procurement Canada (PSPC)
Indigenous Services Canada (ISC)
Global Affairs Canada (GAC)
Canadian International Trade Tribunal (CITT)
Patented Medicine Prices Review Board (PMPRB)
Canada Foundation for Innovation
Finance Canada (FIN)
House of Commons
National Defence (DND)
Federal Economic Development Agency for Southern Ontario (FedDev)
Agriculture and Agri-Food Canada (AAFC)
Veterans Affairs Canada (VAC)
National Research Council (NRC)
Competition Bureau Canada (COBU)
Canada Revenue Agency (CRA)
Public Health Agency of Canada (PHAC)
International Development Research Centre (IDRC)
Privy Council Office (PCO)
Senate of Canada
Natural Sciences and Engineering Research Council (NSERC)
Health Canada (HC)
Canadian Northern Economic Development Agency (CanNor)
Prime Minister's Office (PMO)
Innovation, Science and Economic Development Canada (ISED)
Canada Economic Development for Quebec Regions
Acts: Patent Act
Government funding received:
Lobbying activity details:
Public health and prevention programs including the Public Health Agency of Canada and efforts to support the development and procurement of innovative vaccines and therapies to address major public health issues such as COVID-19 and RSV.
Annual federal Budgets and Budget updates relating to the biopharmaceutical industry.
Engage with Canadian government officials to discuss and provide input on Canada’s countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry, as well as free trade agreements as they relate to the biopharmaceutical industry
Scientific Research and Experimental Development (SR&ED) Tax Incentive Program regarding eligible expenditures.  Discussions on policies such as "patent box" and Investment Tax Credits.
Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products
Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products
Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
Engagement with the Government regarding the Strategic Response Fund (SRF) (previously known as SIF) and investment in Canada
Establish accountability with Health Canada, Canada’s Drug Agency and the pan-Canadian Pharmaceutical Alliance, as well as Regulations, policies and programs related to the review and reimbursement processes
Common Drug Review Policies as it relates to reimbursement recommendation decision-making process and framework
Federally-funded Public Drug Plans, including the Non Insured Health Benefits program, with respect to reimbursement for drug products for beneficiaries.
Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes
Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations